Follow us for updates
© 2020
Read the Story →

AstraZeneca Vaccine Gets Emergency Use Authorization in Philippines

After Pfizer.
by Arianne Merez
Just now
Photo/s: Shutterstock

The COVID-19 vaccine developed by British pharmaceutical firm AstraZeneca has been authorized for emergency use in the Philippines, the Food and Drug Administration said Thursday.

AstraZeneca's COVID-19 vaccines are projected to cost P610 for two doses, among the cheapest based on available pricing. The vaccine, developed with the Univeristy of Oxford is the second to secure emergency use authorization in the Philippines, Director-General Eric Domingo of the FDA said.

"It is decided that all conditions for an EUA are present and that the benefit of using the vaccine outweighs the known and potential risks," Domingo said.

Granting an EUA to a vaccine would expedite its availability to the people who need it the most. In the case of the COVID-19 pandemic, the Philippine government is rushing to make vaccines available to the most vulnerable to the virus: medical frontliners, and the elderly.


These are the LGUs Ordering AstraZeneca's COVID Vaccine

Continue reading below ↓

Philippines Orders More AstraZeneca COVID Vaccines

AstraZeneca earlier said that its COVID-19 vaccine, which was developed with the University of Oxford has shown "an average efficacy of 70%" in trials. The results ranged between 62% and 90% efficacy depending on the vaccine dosage.

This is lower compared with the efficacy of coronavirus vaccines trialed by rivals Pfizer/BioNTech and Moderna which have come in at around 95%, but higher than China's Sinovac which has come in at 50.4% in the latest trial.


COVID-19 Vaccines in the Philippines: Price, Efficacy, Status

The Philippines has ordered some 17.7 million doses of AstraZeneca's COVID-19 vaccines.

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.